1. Home
  2. GEVO vs MNPR Comparison

GEVO vs MNPR Comparison

Compare GEVO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$1.90

Market Cap

474.9M

Sector

Industrials

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$58.27

Market Cap

421.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
MNPR
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.9M
421.0M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
GEVO
MNPR
Price
$1.90
$58.27
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$6.42
$101.42
AVG Volume (30 Days)
2.9M
311.8K
Earning Date
03-05-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$120,932,000.00
N/A
Revenue This Year
$913.54
N/A
Revenue Next Year
$11.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
675.75
N/A
52 Week Low
$0.92
$26.06
52 Week High
$2.95
$105.00

Technical Indicators

Market Signals
Indicator
GEVO
MNPR
Relative Strength Index (RSI) 44.81 35.17
Support Level $1.72 $56.22
Resistance Level $1.94 $61.20
Average True Range (ATR) 0.12 4.65
MACD -0.01 -1.13
Stochastic Oscillator 33.65 9.07

Price Performance

Historical Comparison
GEVO
MNPR

About GEVO Gevo Inc.

Gevo Inc is a next-generation diversified energy company committed to fueling America's future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Its technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. The business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: